Aldesleukin (IL-2)

BIOLOGICAL3 trials

Sponsors

M.D. Anderson Cancer Center, United Therapeutics, Alaunos Therapeutics

Conditions

Adenocarcinoma of LungAdenosquamous Cell Lung CancerCholangiocarcinomaColorectal CancerEndometrial CancerGynecologic CancerMelanomaNeuroblastoma

Phase 1

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

CompletedNCT01592045

United TherapeuticsNeuroblastoma

Start: 2012-08-31End: 2014-06-30Updated: 2015-09-23

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

TerminatedNCT05194735

Alaunos TherapeuticsAdenocarcinoma of Lung, Adenosquamous Cell Lung Cancer, Cholangiocarcinoma +9

Start: 2022-04-04End: 2023-08-14Updated: 2025-11-07

Phase 3

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

CompletedNCT00002882

M.D. Anderson Cancer CenterMelanoma, Skin Cancer

Start: 1995-11-30End: 2006-04-30Updated: 2011-12-13

Related Papers

Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared <i>KRAS</i> and <i>TP53</i> mutations expressed by solid tumors in first-in-human phase 1 study.

Journal of Clinical Oncology2023-06-018 citations

First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-012 citations